University of Sussex
Browse

File(s) under permanent embargo

COVID-19 mortality in patients on anticoagulants and antiplatelet agents

journal contribution
posted on 2023-06-07, 07:29 authored by Helena Sivaloganathan, Eleni E Ladikou, Timothy ChevassutTimothy Chevassut
Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D-dimer and fibrinogen levels (Al-Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang, et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID-19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID-19 (Klok, et al 2020, Stoneham, et al). The term “diffuse pulmonary intravascular coagulopathy” has been proposed to describe the lung-restricted vascular immunopathology associated with COVID-19. This is distinct from disseminated intravascular coagulation in its early stages and is characterised by increased D-dimer with normal platelet count and normal/elevated fibrinogen (McGonagle, et al 2020). Increased VTE rate has been associated with higher D-dimer level, and in the same study, an association between VTE and death was found (Middeldorp, et al 2020). Another study has shown a D-dimer greater than 1 µg/mL was associated with a poorer prognosis (Zhou, et al 2020). Patients requiring mechanical ventilation who were treated with therapeutic anticoagulation had an in-hospital mortality of 29.1% compared to 62.7% in patients who did not receive anticoagulation. Longer duration of anticoagulation was associated with a reduced risk of mortality (Paranjpe, et al 2020).

Funding

Mining the Wnt signalling-responsive surfaceome for drug targets in acute myeloid leukaemia; G3090; WELLCOME TRUST

How does SARS CoV-2 infect blood vessels?; G3146; UK RESEARCH AND INNOVATION; MR/V036750/1

Modelling and targeting Acute Myeloid Leukaemia cells in the Bone Marrow protective niche; G3106; SUSSEX CANCER FUND FOR TREATMENT AND RESEARCH

Drug-induced selective lethality in populations of DNMT3A knockdown cells; G2782; WELLCOME TRUST; 218435/Z/19/Z

In vitro modelling and therapeutic targeting of tumour cell migration in chronic lymphocytic leukaemia.; G2544; BLOODWISE

History

Publication status

  • Published

File Version

  • Accepted version

Journal

British Journal of Haematology

ISSN

0007-1048

Publisher

Wiley

Department affiliated with

  • Clinical and Experimental Medicine Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date

2020-07-10

First Compliant Deposit (FCD) Date

2020-07-09

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC